EXACT THERAPEUTICS AS ANNOUNCES CHANGES TO THE MANAGEMENT TEAM
OSLO/LONDON, OCTOBER 19th 2021: EXACT THERAPEUTICS AS (“EXACT-Tx” or the “Company”), a clinical stage precision medicine company utilising Acoustic Cluster Therapy (ACT®) across multiple therapeutic areas, today announced changes to the management team.
Dr Rafiq Hasan has decided to step down as CEO of the Company to pursue other business interests. Before joining EXACT-Tx, Dr Hasan spent more than 15 years in Ophthalmology and is now looking to move back into the sector. During his tenure at EXACT-Tx, Dr Hasan has established a strong management team and prepared the company to restart recruitment into the Phase I ACTIVATE study in the coming months.
Dominic Moreland, currently CFO will assume the additional Interim CEO position and Dr Masha Strømme will assume the position of Executive Chair during the recruitment process for a successor to Dr Hasan. Dominic and Masha will work with Dr Hilary McElwaine-Johnn (CMO of EXACT-Tx) to ensure an orderly transition of leadership and smooth continuation of pre-clinical and clinical development activities.
Dr Masha Strømme, Chair of the Board of Directors of EXACT-Tx commented “I would like to thank Rafiq for his dedicated work for the Company and wish him every success in the future”.
About ACT®
ACT® is a proprietary formulation consisting of microbubbles and microdroplets that are activated through the application of ultrasound with the consequent increase in targeted delivery of a co-administered therapeutic agent.
ACT® is supported by a strong and broad preclinical package demonstrating therapeutic enhancement in multiple oncology models (pancreatic, breast, colon, prostate) as well as blood-brain barrier penetration.
The initial focus of the company is oncology, however the ACT® platform has potential across several therapeutic areas (infectious diseases, CNS, immunotherapy) and product classes.
About EXACT
EXACT-Tx is a clinical stage Norwegian biotech company developing a technology platform for targeted therapeutic enhancement – Acoustic Cluster Therapy (ACT®). ACT® sonoporation is a unique approach to ultrasound-mediated, targeted drug enhancement – with the potential to significantly amplify the clinical utility of a wide range of therapeutic agents across a multitude of indications including within oncology (chemotherapy, immunotherapy), infectious diseases, and neurological conditions. www.exact-tx.com
For more information contact:
Dominic Moreland
CFO and Interim CEO
dominic@exact-tx.com